Interactive Investor
>>

Opthea Ltd (ASX:OPT) Share Price

OPT

Opthea Ltd

APAC company

Right Arrow 1

Healthcare

Right Arrow 2

Biotechnology

 / 

- / -
-
- / -
-
-
-

Bid

-

Ask

-

Last Traded

-

Chg

-

-

XASX

-

Updated: -

Research

News & analysis

Loading...

Times are shown in GMT+11, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.

This stock can be held in:

 / 

- / -
-
- / -
-
-
-

Company Profile

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.Opthea Ltd, formerly Circadian Technologies Ltd develops and commercializes therapies for cancer, eye diseases, and others. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets.

ASX:OPT

AU000000OPT2

AUD

Loading...

Loading Comparison

Latest OPT News